Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN

NCT ID: NCT06877221

Last Updated: 2025-06-19

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 204 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-25
• Study Completion Date: 2030-12-31

Brief Summary

Prospective, multicenter, randomized, controlled, blinded, and superiority - designed; The target population undergoes a screening treatment with prescribed medications for at least 4 weeks. Eligible subjects are randomly assigned to the experimental group and the control group at a ratio of 2:1. The experimental group is treated with the ultrasound nerve ablation catheter and the ultrasound nerve ablation device of Shenzhen Maiwei Medical Technology Co., Ltd., while the control group only undergoes renal arteriography (regarded as a sham operation). Within 6 months after the operation, both groups continue to receive antihypertensive drug treatment with the dosage and types specified during the screening period. The subjects are kept blinded during the study. The relative change values of the average 24 - hour ambulatory systolic blood pressure from the baseline at 6 months after the operation are compared between the two groups.

Conditions

Refractory Hypertension or Drug-intolerant Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

ultrasound renal denervation

Group Type: EXPERIMENTAL

ultrasound renal denervation

Intervention Type: PROCEDURE

Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device

Renal arteriography

Group Type: SHAM_COMPARATOR

ultrasound renal denervation

Intervention Type: PROCEDURE

Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device

Interventions

ultrasound renal denervation

Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Age between 18 and 70 years old (calculated based on the date of starting standardized medication).

2. After treatment with at least two types of antihypertensive drugs for 4 weeks or more, the clinic systolic blood pressure is ≥140 mmHg and ≤180 mmHg, and the average 24 - hour ambulatory systolic blood pressure is ≥130 mmHg (or the daytime ambulatory systolic blood pressure is ≥135 mmHg).

3. Resting heart rate ≥70 beats per minute without taking beta - blockers (this criterion does not apply to patients taking beta - blockers).

4. The subject agrees to participate in this clinical trial, complies with the follow - up required by the trial protocol, and has voluntarily signed the informed consent form

Exclusion Criteria

1. CTA, MRA, or DSA examination shows that the shape and structure of the unilateral or bilateral renal arteries are not suitable for ablation surgery (renal artery stenosis exceeding 50%, renal artery aneurysm, fibromuscular dysplasia of the renal artery, or the diameter of the main renal artery is less than 3 mm).

2. Having only one kidney or having received a kidney transplant.

3. Having a history of renal artery interventional treatment or renal denervation surgery.

4. Suffering from any condition that may affect the accuracy of blood pressure measurement, such as the upper arm diameter being too large relative to the cuff.

5. Secondary hypertension (excluding apnea syndrome).

6. Glomerular filtration rate (eGFR) < 45 mL/min/1.73m² (MDRD formula).

7. Having a history of hospitalization due to hypertensive crisis within one year before randomization for enrollment.

8. Suffering from type 1 diabetes.

9. Suffering from primary pulmonary hypertension.

10. Being allergic to contrast agents.

11. Severe cardiac valve stenosis.

12. Cardiac insufficiency (NYHA class III - IV).

13. Hyperthyroidism or hypothyroidism.

14. Requiring mechanical ventilation for assisted breathing (except for nocturnal respiratory support for treating sleep apnea).

15. Acute or severe systemic infection.

16. Having an implantable cardioverter - defibrillator (ICD) or pacemaker.

17. Having obvious symptoms of active peptic ulcer (such as abdominal pain, nausea, vomiting, regurgitation, etc.).

18. Having obvious bleeding tendency and hematological diseases.

19. Having a history of surgery or trauma requiring hospitalization within 30 days before randomization for enrollment.

20. Having a cardiovascular event (stable or unstable angina, myocardial infarction) or cerebrovascular event (stroke, cerebrovascular accident, transient ischemic attack) within 6 months before randomization for enrollment.

21. Pregnant, lactating women, or women planning to become pregnant during the study period.

22. Currently participating in other clinical trials of drugs or medical devices.

23. Other reasons that the investigator deems inappropriate for participation in this study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shenzhen Pulsecare Medical Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Jingfeng J wang, Postdoctoral fellow

Role: CONTACT

wangjingfeng2017@163.com

020-81332199 ext. 0000

Facility Contacts

Jingfeng Wang J Wang

Role: primary

wangjingfeng2017@163.com

189 2891 6398

Other Identifiers

MW-URDN202501

Identifier Type: -

Identifier Source: org_study_id